NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NYSE American · Biotechnology · USD

NeurAxis, Inc. (NRXS) Stock Analysis

NeurAxis, Inc. (NRXS) is a Biotechnology stock listed on NYSE American and quoted in US Dollar.

Last Updated: October 21, 2026

NRXS

$7.92

+$0.10 (+1.28%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NRXS with… →

NRXS Key Statistics

As of Oct 21, 2026
Trading
Open
$7.84
Previous Close
$7.82
Day's Range
7.72–8.05
52-Week Range
2.21–9.33
Volume
66.94K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.37
Valuation
Market Cap
$99.46M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
18.71
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.78
Financials (FY)
Revenue (FY)
$3.57M+32.89%
Net Income (FY)
−$7.80M
Profit marginThe share of revenue left as profit after all costs and taxes.
−144.44%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
12.56M
1-Year Return
+114.05%
Dividend and dates
Avg Volume
129.34K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, NRXS closed at $7.92, +114.05% over 1 year.

NeurAxis, Inc. (NRXS) has a market capitalization of $99.46M.

In fiscal 2025, NRXS reported revenue of $3.57M.

NRXS Stock Return by Calendar Year

NeurAxis, Inc. (NRXS) return since Aug 2023: what $10,000 became

1 year
$10,000 $21,405
+114.05%
3 years
$10,000 $27,887
+178.87%
Since Aug 2023
$10,000 $13,200
+32.00%

If you had invested $10,000 in NeurAxis, Inc. (NRXS) at the close on August 9, 2023, the earliest close on record here, it would have been worth $13,200 at the close on October 21, 2026: +32.00% in total, +9.06% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+74.45%
2025+93.19%
2024−11.99%
2023 (partial year)−55.50%

As of October 21, 2026.

NRXS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$3.57M−$7.80M−218.5%
2024$2.69M−$8.24M−306.8%
2023$2.46M−$14.63M−594.6%
2022$2.68M−$4.78M−178.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$3.57M$3.01M−$7.83M−$7.80M−218.5%
2024$2.69M$2.32M−$7.16M−$8.24M−306.8%
2023$2.46M$2.16M−$6.66M−$14.63M−594.6%
2022$2.68M$2.39M−$3.37M−$4.78M−178.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

NRXS Valuation vs Biotechnology Median

Median of 608 stocks
MetricNRXSBiotechnology medianvs median
P/S ratio18.7113.3041% above
Profit margin−144.44%−38.31%106.1 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

NeurAxis, Inc. (NRXS) is capitalised at $99.46M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 24.

The most recent close on file for NRXS is $7.92, dated October 21, 2026. That is +$0.10 (+1.28%) against the previous close. The 52-week range on file runs from $2.21 to $9.33. The latest close sits 258.37% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $3.57M. Against the prior fiscal year total of $2.69M, that is a change of +32.89%. The same year closed with a net loss of $7.80M. Profit margin runs at −144.44%. That is 106.1 percentage points below the Biotechnology median of −38.31%. Trailing earnings per share are −0.78.

Across the 4 fiscal years on file, revenue moves from $2.68M in 2022 to $3.57M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 18.71 times revenue. On price-to-sales that is 40.68% above the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the total return is +114.05%. Across 3 years the annualized return works out at +40.76%. Beta against the wider market is reported at 1.37. Daily returns over the trailing 3 years annualize to a volatility of 91.76%.

Growth & Income

The record shows no dividend for NRXS.

Across the complete calendar years on file, 2025 returned +93.19% and 2024 returned −11.99%. 2026 is still running; the total return is +74.45% year to date.

Peer Comparison

NeurAxis, Inc. (NRXS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
NeurAxis, Inc. NRXS $99.46M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. NeurAxis, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About NeurAxis, Inc.

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. The company also offers rectal expulsion device, a screening tool that helps to detects evacuation disorders. It sells its products to healthcare companies, such as hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. NeurAxis, Inc. was founded in 2011 and is headquartered in Carmel, Indiana.

Visit website →